CF
AMLX icon

Cantor Fitzgerald’s Amylyx Pharmaceuticals AMLX Stock Holding History

Cantor Fitzgerald’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50,000
Closed -$321K – 377
2025
Q2 		$321K Sell
50,000
-50,000
-50% -$243K 0.01% 262
2025
Q1 		$354K Buy
+100,000
New +$356K 0.01% 174

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cantor Fitzgerald's AMLX Position: Q3 2025 in Review

Cantor Fitzgerald sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2025, closing a stake of 50,000 shares — an estimated $321K sold.

Cantor Fitzgerald first reported a position in AMLX in Q1 2025 and held it in 2 quarters. The position peaked at $354K in Q1 2025. 169 funds tracked by Wall St. Rank hold AMLX as of Q3 2025.

  • Cantor Fitzgerald reported no remaining Amylyx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 50,000 Amylyx Pharmaceuticals shares in Q3 2025, an estimated $321K.
  • Cantor Fitzgerald first reported a position in Amylyx Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Cantor Fitzgerald's Amylyx Pharmaceuticals position peaked at $354K in Q1 2025.
  • 169 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2025.

Based on Cantor Fitzgerald's 13F filing for Q3 2025, filed 14 Nov 2025.